Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...
To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...
It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other ...
Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...
Vetigenics is seeing encouraging results of a completed study for an antibody aimed at treating oral melanoma in dogs, used ...
Financial writer advises caution on Jyong Biotech Ltd. IPO due to high debt, legal issues, and FDA challenges. Click for my ...
Oncolytics Biotech (ONCY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
A Peninsula biotech company focusing on a deadly lung-scarring disease lost more than half its stock value Monday after ...
Swiss biotech Bioversys AG shares started trading at 36.5 Swiss francs ($40.29) on the SIX Swiss Exchange on Friday, slightly up from the final price for its initial public offering (IPO) of 36 Swiss ...
January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.
South Korea aims to invest at least 34 trillion won ($23 billion) to help companies develop cutting-edge technologies in the ...
Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...